Table 5.
Changes in neurologic measures
| Measure | 1-Year Retrospective Visit | P Value | Baseline Visit | P Value | 1-Year Follow-Up Visit |
|---|---|---|---|---|---|
| Agalsidase-beta regular-dose group | |||||
| CES-D score | 19.8±9.8 | 0.92 | 18.6±10.1 | 0.45 | 16.1±11.6 |
| GCPS 2 (maximum pain) | 5.1±3.8 | 0.43 | 4.3±3.7 | 0.74 | 4.2±3.6 |
| GCPS 5 (impairment) | 2.7±2.6 | 0.37 | 2.2±2.8 | 0.45 | 2.3±3.3 |
| NPSI sum score | 0.18±0.21 | 0.74 | 0.18±0.25 | 0.86 | 0.21±0.25 |
| Sural nerve | |||||
| SNAP (n=11) (µV) | 13.8±6.5 | 0.38 | 16.2±8.5 | 0.86 | 15.1±7.2 |
| NCV (m/s) | 41.0±2.9 | 0.44 | 43.1±4.1 | 0.65 | 43.2±5.1 |
| CDT | −15.7±6.2 | 0.20 | −16.2±7.1 | 0.57 | −13.4±7.8 |
| Agalsidase-beta dose-reduction group | |||||
| CES-D score | 15.0±9.7 | 0.05 | 15.3±12.4 | 0.91 | 20.8±10.6 |
| GCPS 2 (maximum pain) | 5.1±2.9 | 0.49 | 4.1±2.6 | 0.67 | 5.3±2.8 |
| GCPS 5 (impairment) | 1.5±1.9 | 0.08 | 2.0±2.9 | 0.85 | 3.6±2.6 |
| NPSI sum score | 0.20±0.18 | 0.54 | 0.19±0.25 | 0.25 | 0.40±0.24 |
| Sural nerve | |||||
| SNAP (n=12) (µV) | 15.5±9.1 | 0.49 | 18.4±11.0 | 0.64 | 15.5±13.8 |
| NCV (m/s) | 45.0±4.3 | 0.72 | 44.6±5.9 | 0.19 | 46.2±5.4 |
| CDT | −14.7±7.8 | 0.90 | −16.6±7.7 | 0.12 | −14.9±8.6 |
| Agalsidase-alfa switch group | |||||
| CES-D score | 17.4±12.6 | 0.25 | 15.0±8.7 | 0.23 | 17.7±12.6 |
| GCPS 2 (maximum pain) | 6.9±2.5 | 0.08 | 4.0±3.3 | 0.59 | 4.4±3.0 |
| GCPS 5 (impairment) | 4.4±3.2 | 0.20 | 2.2±3.2 | 0.46 | 2.4±3.3 |
| NPSI sum score | 0.22±0.02 | 0.10 | 0.13±0.12 | 0.19 | 0.21±0.19 |
| Sural nerve | |||||
| SNAP (n=15) (µV) | 19.2±12.8 | 0.74 | 17.4±12.9 | 0.95 | 16.5±8.3 |
| NCV (m/s) | 46.2±6.4 | 0.07 | 42.8±8.1 | 0.20 | 45.9±6.3 |
| CDT | −10.5±6.2 | 0.32 | −11.5±8.2 | 0.68 | −10.4±6.5 |
Data are presented as mean±SD. CES-D, Center for Epidemiologic Studies-Depression Scale; SNAP, sensory nerve action potential; NCV, nerve conduction velocity; CDT, cold detection threshold.